Dailypharm Live Search Close

Hanmi is the first to release Zytiga generic at half price

By Lee, Tak-Sun | translator Kim, Jung-Ju

23.09.22 12:10:53

가나다라 0
Same-ingredient prostate cancer treatment will be listed for reimb on the first of next month

The first generic to be developed by a Korean company after passing the difficult bioequivalence testing standards


Hanmi Pharm has become the first to launch the first generic of Janssen's prostate cancer treatment ‘Zytiga (abiraterone acetate).’

In particular, the drug is expected to greatly reduce the financial burden borne by patients as it is sold at a much lower price than the original Zytiga.

According to industry sources on the 22nd, Hanmi Pharm’s 'Abiteron Tab 500mg' will be listed for reimbursement on the 1st of next month.

The drug is a generic that contains the same ingredients as Zytiga and is the first generic to be listed for reimbursement.

Its insurance price ceiling is KRW 8,537 per tablet, which is almost half of that of Zytiga, which is KRW 16,780. It

Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)